Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity: A retrospective analysis

Cancer

Volumn 110, Issue 9, 2007, Pages 2050-2060

  Canter, Robert J ^a   Qin, Li Xuan ^a   Downey, Robert J ^a   Brennan, Murray F ^a   Singer, Samuel ^a   Maki, Robert G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Long term impact; Perioperative chemotherapy; Pulmonary metastasectomy; Soft tissue sarcoma; Survival

Indexed keywords

DACARBAZINE; DOCETAXEL; DOXORUBICIN; FLAVOPIRIDOL; GEMCITABINE; IFOSFAMIDE; MESNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GENDER; HUMAN; LUNG METASTASIS; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SOFT TISSUE SARCOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; EXTREMITIES; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; PERIOPERATIVE CARE; PULMONARY SURGICAL PROCEDURES; RETROSPECTIVE STUDIES; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 35648941713     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23023     Document Type: Article

References (23)

1. Gadd MA, Casper ES, Woodruff JM, et al. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg. 1993;218:705-712.
2. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens - a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol. 1999;17:150-157.
3. Billingsley KG, Lewis JJ, Leung DH, et al. Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer. 1999;85: 389-395.
4. Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg. 1999;229:602-610; discussion 1999;610-612.
5. Casson AG, Putnam JB, Natarajan G, et al. Five-year survival after pulmonary metastasectomy for adult soft tissue sarcoma. Cancer. 1992;69:662-668.
6. Choong PF, Pritchard DJ, Rock MG, et al. Survival after pulmonary metastasectomy in soft tissue sarcoma. Prognostic factors in 214 patients. Acta Orthop Scand. 1995;66:561-568.
7. Robinson MH, Sheppard M, Moskovic E, et al. Lung metastasectomy in patients with soft tissue sarcoma. Br J Radiol. 1994;67:129-135.
8. van Geel AN, Pastorino U, Jauch KW, et al. Surgical treatment of lung metastases: the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer. 1996;77:675-682.
9. Frost DB. Pulmonary metastasectomy for soft tissue sarcomas: is it justified? J Surg Oncol. 1995;59:110-115.
10. Porter GA, Cantor SB, Walsh GL, et al. Cost-effectiveness of pulmonary resection and systemic chemotherapy in the management of metastatic soft tissue sarcoma: a combined analysis from the University of Texas M. D. Anderson and Memorial Sloan-Kettering Cancer Centers. J Thorac Cardiovasc Surg. 2004;127:1366-1372.
11. Lanza LA, Putnam JB Jr, Benjamin RS, et al. Response to chemotherapy does not predict survival after resection of sarcomatous pulmonary metastases. Ann Thorac Surg. 1991;51:219-224.
12. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757-763.
13. Rubin DB. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized trials. Stat Med. 2007;26:20-36.
14. Elkin EB, Hurria A, Mitra N, et al. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006;24:2757-2764.
15. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350:1647-1654.
16. Brennan MF, Singer S, O'Sullivan B, Maki RG. Sarcomas of the Soft Tissue and Bone: Soft Tissue Sarcoma. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 7th ed. Philadelphia, Pa: Lippincott, Williams & Wilkins; 2005:1581-1637.
17. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19:1238-1247.
18. Frustaci S, De Paoli A, Bidoli E, et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology. 2003;2(65 suppl):80-84.
19. Frustaci S, Berretta M, Comandone A, et al. Adjuvant treatment of high-risk adult soft tissue sarcomas: a survey by the Italian Sarcoma Group. Tumori. 2006;92:92-97.
20. Eilber FC, Eilber FR, Eckardt J, et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg. 2004;240:686-695; discussion 695-697.
21. Grobmyer SR, Maki RG, Demetri GD, et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol. 2004;15:1667-1672.
22. Pisters PW. Preoperative chemotherapy and split-course radiation therapy for patients with localized soft tissue sarcomas: home run, base hit, or strike out? J Clin Oncol. 2006;24:549-551.
23. Cormier JN, Huang X, Xing Y, et al. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at 2 cancer centers: chemotherapy-associated outcomes. J Clin Oncol. 2004;22:4567-4574.